tirzepatide patent challenge BPI Labs challenges patent, cites DiMarchi's work | Sabina Hemmi posted on the topic Why Generic Tirzepatide Won't Be

A: BPC-157 is a short peptide studied for tissue protection and inflammation-related pathways, including gastrointestinal and connective tissue models

The Journal of Physiology, 536(Pt 1), 295304.

The effects take place immediately, and for someone who takes a lot of medication, its a lot easier on the bodyespecially on the stomach. [I have a] background in public health, and I can definitely say that through IV therapy youre going to get a lot more benefit getting it through an IV, as opposed to taking something orally

Most diabetes guidelines recommend an A1C target below 7.0 percent for adults with type 2 diabetes, though your individual target may differ based on age, kidney function, and other health factors